NEW YORK (GenomeWeb) – The COPD Foundation-sponsored COPD Biomarker Qualification Consortium (CBQC) said today that it has partnered with diagnostics and biotech manufacturer Bio-Techne to evaluate and qualify a serum-based predictive biomarker for selecting subjects for emphysema clinical trials.

The marker, the soluble form of receptor for advanced glycation end products (sRAGE), has shown promise in scientific studies as an indicator of the presence and/or progression of emphysema, the consortium said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.